Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SAFESKIN -- Ignore unavailable to you. Want to Upgrade?

To: Apple12 who wrote (235)	3/11/1998 4:04:00 PM
From: wmf	Read Replies (1) \| Respond to of 828

It comes from the annual report and mentions 50 lawsuits. It states that these are directed against SFSK and other manufacturers. It does not detail if there are any directed exclusively at SFSK. The SFSK web page has also a cautionary statement about that but gives no detail at all: The most important factors that could prevent the Company from achieving its goals - and cause the assumptions underlying forward-looking statements and the actual results of the Company to differ materially from those expressed in or implied by those forward-looking statements - include, but are not limited to, the following: the competitive nature of the industry and the ability of the Company to continue to distinguish its products on the basis of quality, reliability and value, possible obsolescence of the Company's primary product due to the development by competitors of new products, manufacturing processes or technologies including latex alternatives; the ability of the Company to maintain strong distributor relationships, and the ability of the Company to maintain selling prices and anticipated volumes; the ability of the Company to meet existing or future FDA regulations regarding the manufacture and sale of the Company's gloves; >adverse outcomes regarding product liability lawsuits or the ability >to obtain sufficient product liability insurance coverage at >reasonable rates; the consistent availability, at budgeted prices, of raw rubber from independent growers and concentrate plant operators in Malaysia and Thailand; delays in the completion of the Company's construction of its new production line, referred to by the Company as the "Grand Master," and latex concentrate plant in Thailand or the failure of such new line or plant to generate anticipated productivity and efficiencies; risks associated with investments and operations in foreign countries, particularly Thailand and Malaysia, including those related to local economic conditions, exchange rate fluctuations, governmental policies regarding foreign ownership of manufacturing facilities, local regulatory requirements, tax holidays and political factors; economic conditions in the healthcare industry, including the potential impact of industry consolidation and cost constraints on the end-user; changes in significant government regulations affecting the healthcare industry; the ability of the Company to protect its proprietary products, know-how and manufacturing processes; changes in the Company's rates or basis of income taxation; rapid levels of inflation could have a significant effect on the Company's net sales and profitability